Solid phase binding assay – Clusterin binding to Very Low-Density Lipoprotein Receptor (VLDLR)

By Patricia Yuste Checa, PhD, Andreas Bracher and Franz-Ulrich Hartl, MD
View Published Protocol

Output Details

Description
This protocol details how to monitor Clusterin binding to the Very Low-Density Lipoprotein Receptor (VLDLR) by Enzyme-linked immunosorbent assays (ELISA) adapted from Leeb et al. (2014).
Identifier (DOI)
10.17504/protocols.io.yxmvm36kol3p/v1
Tags
  • CLU (Clusterin)
  • ELISA
  • Protein aggregates
Team
Team Harper
Program
Collaborative Research Network
Theme
PD Functional Genomics

Meet the Authors

Related Research

Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases

Genetic correlation between neurodegenerative and neuropsychiatric diseases was explored using local rg analysis. Unique relationships were found, suggesting shared genetic mechanisms and potential therapeutic targets in complex diseases.

View Article

The chaperone Clusterin in neurodegeneration−friend or foe?

The authors review the diverse functions of Clusterin in the pathogenesis of neurodegenerative diseases, focusing on evidence that Clusterin may act either as a suppressor or enhancer of pathology.

View Article

HEK293E_Clu WT

Cell Line: Transfected with the pB-T-PAF expression plasmid expressing CLU under the tet operator and the PB-RN reverse transactivator plasmid expressing the reverse tetracycline-controlled transactivator under the CMV promoter.

View Lab Material
View More Outputs